Aligos Therapeutics (NASDAQ:ALGS) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Aligos Therapeutics (NASDAQ:ALGS) from a hold rating to a sell rating in a report published on Saturday.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Aligos Therapeutics in a report on Friday, September 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $50.00.

Aligos Therapeutics Price Performance

Shares of ALGS stock traded down $0.03 during trading hours on Friday, hitting $7.07. The stock had a trading volume of 76,332 shares, compared to its average volume of 104,249. The firm has a market capitalization of $43.48 million, a PE ratio of -0.36 and a beta of 2.76. The stock’s 50 day moving average is $9.70 and its 200 day moving average is $8.19. Aligos Therapeutics has a twelve month low of $3.76 and a twelve month high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, November 6th. The company reported ($3.04) EPS for the quarter, missing the consensus estimate of ($2.09) by ($0.95). The business had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $0.50 million. Aligos Therapeutics had a negative net margin of 3,267.65% and a negative return on equity of 40.71%. As a group, equities analysts predict that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. NorthCrest Asset Manangement LLC purchased a new position in Aligos Therapeutics during the third quarter worth about $98,000. XTX Topco Ltd acquired a new position in Aligos Therapeutics during the 2nd quarter worth approximately $100,000. AlphaQuest LLC purchased a new position in shares of Aligos Therapeutics during the 1st quarter worth approximately $130,000. Geode Capital Management LLC lifted its holdings in shares of Aligos Therapeutics by 21.3% in the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock valued at $246,000 after buying an additional 5,978 shares during the period. Finally, Readystate Asset Management LP acquired a new stake in shares of Aligos Therapeutics in the 1st quarter valued at approximately $375,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).